Lyell Immunopharma, Inc.
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 4 insiders sold shares within a monthSince Aug 21, 2026+4.1
Trials
- LYELLyell Immunopharma, Inc.4Calm
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Signing up patientsPhase 3400 patientsMain results: Dec 2029 - LYELLyell Immunopharma, Inc.4Calm
LYL273 for Patients With Relapsed or Refractory mCRC
Signing up patientsPhase 1/2155 patientsMain results: Jun 2028 - LYELLyell Immunopharma, Inc.4Calm
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Signing up patientsPhase 1/2270 patientsMain results: Dec 31, 2028
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
16 sales (14 not pre-planned) · 2 purchases
- ARCH Venture Partners IX, LLCLarge shareholder · Nov 4, 2026Bought 2,321,262 sharesabout $25.0 million ·
- ARCH Venture Fund XIII, L.P.Large shareholder · Nov 4, 2026Bought 2,321,262 sharesabout $25.0 million ·
- Aguirre Jarrad MattieuChief Medical Officer · Oct 12, 2026Sold 422 sharesabout $4 thousand · not pre-planned
- Shook DavidChief Medical Officer · Sep 10, 2026Sold 500 sharesabout $6 thousand · not pre-planned
- Seely LynnPresident and CEO · Aug 21, 2026Sold 9,589 sharesabout $149 thousand · not pre-planned
- Hill Stephen J.Chief Operating Officer · Aug 21, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.